SynAct Pharma AB

SYNACT

SE0008241491

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 06:25:25 2024-04-25 am EDT			5-day change	1st Jan Change
7.095 ^SEK	+2.83%		+5.82%	-19.65%

Mar. 20	Sweden's SynAct Pharma Names New CEO	MT
Mar. 20	SynAct Pharma AB Elects New Board Members and Chairman at Extraordinary General Meeting	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about SynAct Pharma AB

Sweden's SynAct Pharma Names New CEO	Mar. 20	MT
SynAct Pharma AB Elects New Board Members and Chairman at Extraordinary General Meeting	Mar. 20	CI
SynAct Pharma AB Announces CEO Changes	Mar. 20	CI
SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis	Mar. 10	CI
SynAct Pharma AB Announces Resignation of Marina Bozilenko as Member of the Board of Directors	Feb. 27	CI
SynAct Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
SynAct Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 23	CI
SynAct Pharma Announces Additional Data from the Expand P2b Clinical Trial Supporting Continued Development of the Compound in Rheumatoid Arthritis	Feb. 22	CI
SynAct Pharma Names New Chief Medical Officer	Feb. 01	MT
Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024	Feb. 01	CI
Synact Pharma Expands Its Rheumatology Clinical Advisory Board with Three New Highly Experienced Advisors	Jan. 30	CI
SynAct Pharma AB(OM:SYNACT) added to OMX Nordic Small Cap Index	Jan. 04	CI
SynAct Pharma AB(OM:SYNACT) dropped from S&P Global BMI Index	Dec. 18	CI
SynAct Pharma AB Announces Appointments to Nomination Committee	Nov. 22	CI
SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate	Nov. 01	CI
SynAct Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-24	CI
SynAct Pharma AB Announces Additional Data from the Expands P2b Clinical Trial Further Supporting Efficacy and Activity seen in Patients with Elevated CRP	23-10-03	CI
SynAct Pharma AB Announces Additional Data from the EXPAND P2b Clinical Trial and Identifies Population with Responsiveness to Resomelagon	23-09-12	CI
Synact Pharma Announces Top Line Data from the 12-Week Expand P2b Clinical Trial in Severe Active Newly Diagnosed Rheumatoid Arthritis Patients	23-09-04	CI
SynAct Pharma AB Completes Dosing in Part A of Combined Phase 2A/B Resomelagon in Rheumatoid Arthritis (RA)	23-08-17	CI
SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
SynAct Pharma AB Completes Patient Recruitment for Part A of Combined Phase 2a/b RESOLVE Study of Resomelagon in Rheumatoid Arthritis	23-07-20	CI
SynAct Pharma AB Announces the Completion of Dosing in the Phase 2b Expand Study of Resomelagon in Early Severe Rheumatoid Arthritis Patients	23-07-14	CI
Certain Shares of SynAct Pharma AB are subject to a Lock-Up Agreement Ending on 11-JUN-2023.	23-06-10	CI
SynAct Pharma AB Announces Appointment of Thomas Von Koch as Board Member	23-05-25	CI

SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Sector

Biotechnology & Medical Research

Calendar

2024-05-16 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYNACT PHARMA AB	-19.65%	22.54M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.23%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B